Formononetin promotes cell cycle arrest via downregulation of akt/cyclin D1/CDK4 in human prostate cancer cells

Cellular Physiology and Biochemistry

Volumn 34, Issue 4, 2014, Pages 1351-1358

  Li, Tianyu ^a   Zhao, Xinge ^b   Mo, Zengnan ^a   Huang, Weihua ^a   Yan, Haibiao ^a   Ling, Zhian ^a   Ye, Yu ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUILIN MEDICAL UNIVERSITY   (China)

Author keywords

Akt; CDK4; Cyclin D1; Formononetin; Prostate cancer

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; FORMONONETIN; PROTEIN KINASE B; CDK4 PROTEIN, HUMAN; ISOFLAVONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTT ASSAY; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; MALE; NUDE MOUSE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; DOWN-REGULATION; G0 PHASE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; ISOFLAVONES; MALE; MICE; MICE, NUDE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84908642751     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000366342     Document Type: Article

References (32)

1. Hsing AW, Chokkalingam AP: Prostate cancer epidemiology. Front Biosci 2006;11:1388-1413.
2. Gomella LG, Johannes J, Trabulsi EJ: Current prostate cancer treatments: effect on quality of life. Urology 2009;73:S28-S35.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
4. Hemminki K, Rawal R, Bermejo JL: Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. Int J Cancer 2005;113:312-315.
5. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD: Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004;119:174-186.
6. Wolk A: Diet, lifestyle and risk of prostate cancer. Acta Oncol 2005;44:277-281.
7. Chen J, Liu L, Hou R, Shao Z, Wu Y, Chen X, Zhou L: Calycosin promotes proliferation of estrogen receptor-positive cells via estrogen receptors and ERK1/2 activation in vitro and in vivo. Cancer Lett 2011;308:144-151.
8. Zhao R, Xiang N, Domann FE, Zhong W: Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr Cancer 2009;61:397-407.
9. Mu H, Bai YH, Wang ST, Zhu ZM, Zhang YW: Research on antioxidant effects and estrogenic effect of formononetin from Trifolium pratense (red clover). Phytomedicine 2009;16:314-319.
10. Zhang S, Tang X, Tian J, Li C, Zhang G, Jiang W, Zhang Z: Cardioprotective effect of sulphonated formononetin on acute myocardial infarction in rats. Basic Clin Pharmacol Toxicol 2011;108:390-395.
11. Fang SC, Hsu CL, Lin HT, Yen GC: Anticancer effects of flavonoid derivatives isolated from Millettia reticulata Benth in SK-Hep-1 human hepatocellular carcinoma cells. J Agric Food Chem 2010;58:814-820.
12. Auyeung KK, Ko JK: Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell. Invest New Drugs 2010;28:1-13.
13. Gyémánt N, Tanaka M, Antus S, Hohmann J, Csuka O, Mándoky L, Molnár J: In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells. In Vivo 2005;19:367-374.
14. Seo EK, Kim NC, Mi Q, Chai H, Wall ME, Wani MC, Navarro HA, Burgess JP, Graham JG, Cabieses F, Tan GT, Farnsworth NR, Pezzuto JM, Kinghorn AD: Macharistol, a new cytotoxic cinnamylphenol from the stems of Machaerium aristulatum. J Nat Prod 2001;64:1483-1485.
15. Huang WJ, Bi LY, Li ZZ, Zhang X, Ye Y: Formononetin induces the mitochondrial apoptosis pathway in prostate cancer cells via downregulation of the IGF-1/IGF-1R signaling pathway. Pharm Biol 2014;52: 466-470.
16. Chen J, Zeng J, Xin M, Huang W, Chen X: Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm Metab Res 2011;43:681-686.
17. Konishi N, Shimada K, Ishida E, Nakamura M: Molecular pathology of prostate cancer. Pathol Int 2005;55:531-539.
18. Smith S, Sepkovic D, Bradlow HL, Auborn KJ: 3,3'-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells. J Nutr 2008;138:2379-2385.
19. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE: Androgen receptor and invasion in prostate cancer. Cancer Res 2008;68:1128-1135.
20. Suzuki H, Ueda T, Ichikawa T, Ito H: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003;10:209-216.
21. Linja MJ, Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T: Expression of ERalpha and ERbeta in prostate cancer. Prostate 2003;55:180-186.
22. Pan MH, Ghai G, Ho CT: Food bioactives, apoptosis, and cancer. Mol Nutr Food Res 2008;52:43-52.
23. Pan MH, Ho CT: Chemopreventive effects of natural dietary compounds on cancer development. Chem Soc Rev 2008;37:2558-2574.
24. Hilakivi-Clarke L, Wang C, Kalil M, Riggins R, Pestell RG: Nutritional modulation of the cell cycle and breast cancer. Endocr Relat Cancer 2004;11:603-622.
25. Gulappa T, Reddy RS, Suman S, Nyakeriga AM, Damodaran C: Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells. Cancer Lett 2013;337:177-183.
26. Vermeulen K, Van Bockstaele DR, Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-149.
27. Hall M, Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
28. Hilakivi-Clarke L, Wang C, Kalil M, Riggins R, Pestell RG: Nutritional modulation of the cell cycle and breast cancer. Endocr Relat Cancer 2004;11:603-622.
29. Dickson MA, Schwartz GK: Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009;16:36-43.
30. Hallstrom TC, Nevins JR: Balancing the decision of cell proliferation and cell fate. Cell Cycle 2009;8:532-535.
31. Serrano ML, Sánchez-Gómez M, Bravo MM, Yakar S, LeRoith D: Differential expression of IGF-I and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines. Horm Metab Res 2008;40:661-667.
32. Ma X, Hu Y: Targeting PI3K/Akt/mTOR cascade: the medicinal potential, updated research highlights and challenges ahead. Curr Med Chem 2013;20:2991-3010.